Get our newsletter delivered directly to your inbox
I have already subscribed | Do not show this message again
Your email has been successfully registered.
In September, Brazilian Butantan Institute and China's vaccine developer Sinovac Biotech signed an agreement to conduct phase 3 of COVID-19 vaccine's clinical trials in Brazil.
Brazil's National Health Surveillance Agency (ANVISA) Wednesday announced the resumption the Chinese COVID-19 CoronaVac vaccine candidate's clinical trials, which are being conducted in collaboration with the Brazilian Butantan Institute.
The announcement comes just one day after ANVISA decided to suspend phase 3 of CoronaVac clinical trials on Tuesday, following the death of a volunteer who committed suicide, according to a report by the local media TV Globo.
In a note, Butantan Institue director Dimas Covas noted that the resumption of the tests was "excellent news", adding his hopes to continue the clinical study "as soon as possible."
Meanwhile, ANVISA representatives informed that the "serious adverse event" that led to the suspension of the clinical trials is still being investigated, pointing out that no personal information will be released in accordance with the privacy and integrity rights of the volunteers.
Coronavirus: Global death toll passes 1 million – tally: The United States, Brazil and India account for nearly 45% of all COVID-19 deaths globally, with the Latin American region alone responsible for more than a third of them. https://t.co/cAKUhglXsZ JPost pic.twitter.com/rQrfDWY1dY